RxDoctor Payments Data

Lily Phan

Family · Lawrenceville, GANPI 1316432578

Payments from drug & device makers

$2,588in general payments, 2019–2025

Across 104 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$990
  • AbbVie$194
  • Novo Nordisk$186
  • Vanda Pharmaceuticals Inc.$156
  • Abbott$147
  • GSK$105
  • plus $809 from 16 others

What the payments were for

  • Consulting fees$80031%
  • Travel & lodging$803%
  • Food & beverage$1,70866%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,588 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$86,130
Medicare patients
272
Services billed
2,901

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$96,179
JardianceEmpagliflozin18$26,386
FarxigaDapagliflozin Propanediol16$23,985
TrulicityDulaglutide15$16,211
TradjentaLinagliptin17$14,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,218
Atorvastatin Calcium253$1,856
Levothyroxine Sodium165$1,583
Gabapentin81$1,457
Albuterol Sulfate HfaAlbuterol Sulfate49$1,445
Duloxetine Hcl33$1,090
Losartan Potassium110$1,088
Omeprazole78$992
Amlodipine Besylate211$981
Nano 2nd Gen Pen NeedlePen Needle, Diabetic12$981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$186$96,17959 claims
Boehringer IngelheimJardiance, Tradjenta$76$40,42635 claims
AstraZenecaFarxiga$65$23,98516 claims
Lilly USA, LLCTrulicity$84$16,21115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →